ArticleMolecular biology reports2026
Investigation of the azithromycin resistance rate and related genes involved in this resistance in clinical Shigella species collected from children with diarrhea in Ahvaz, Southwest Iran.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the azithromycin resistance rate and the related genes in clinical Shigella species obtained from children with diarrhea in Ahvaz, southwest Iran. METHODS AND
resultsShigella isolates were collected from children with diarrhea and identified using biochemical tests and polyvalent antisera. Antibiotic susceptibility testing was performed using disk diffusion. Minimum inhibitory concentrations (MICs) of azithromycin were determined by the agar dilution method in the presence and absence of efflux inhibitor, phenylalanine-arginine β-naphthylamide (PAβN) (20 µg/ml). The presence of macrolide-associated resistance genes was investigated by polymerase chain reaction. In total, 126 Shigella isolates, including S. sonnei (61.11%, n = 77), S. flexneri (34.92%, n = 44), and S. boydii (3.97%, n = 5) were detected. High resistance rates to nalidixic acid (99.20%), ampicillin (91.27%), cefazolin (84.13%), and trimethoprim-sulfamethoxazole (73.01%) were found among the Shigella isolates, with 77.0% classified as multidrug-resistant (MDR) (non-susceptibility to at least 1 antibiotic in ≥ 3 and < 6 antimicrobial categories) and 17.46% as extensively drug-resistant (XDR) (non-susceptibility to at least 1 antibiotic in ≥ 6 antimicrobial categories). Based on MICs results, 67.46% (n = 85) of isolates were azithromycin-resistant. In 8 (9.41%) azithromycin-resistant isolates, MICs were reduced in the presence of PAβN. Prevalence of mphA and ermB genes among azithromycin-resistant isolates was 98.82% and 8.23%, respectively. A significant relationship between azithromycin resistance and the presence of the mphA gene was observed.
conclusionsThis study highlighted a concerning level of azithromycin resistance that is a main challenge for the treatment of MDR Shigella species in the studied region. Furthermore, the presence of mphA and ermB genes are main mechanisms of azithromycin resistance in southwest of Iran. Further studies with focus on other resistance mechanisms including efflux pump genes (ompA, ompW, various msr and mef) are needed.
Indexed as
Identifiers
41632379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.